Fluoroestradiol F-18 (FES PET)
A PET scan that shows which breast cancer deposits still have oestrogen receptors, helping decide whether hormone therapy will work when biopsy is impractical.
Approved May 2020 as an adjunct to biopsy in recurrent or metastatic ER+ breast cancer. Predicts endocrine responsiveness and reveals heterogeneous ER loss; entered NCCN guidelines 2024. Also used in trials of ER degraders (PET occupancy) and in ER+ ovarian/endometrial research.
- Medicare
- Part B (clinician-administered)
Diagnostic radiopharmaceutical billed with the PET/CT scan under Part B; Cerianna is approved as an adjunct to biopsy for oestrogen receptor-positive lesions in recurrent or metastatic breast cancer.
- Commercial insurance
- variable
Newer tracer; many commercial plans still class FES PET as investigational or cover only when biopsy is not feasible.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B) · Medicare.gov: Diagnostic non-laboratory tests (imaging). Not medical or financial advice; verify with your plan.
- Notes
- No UK marketing authorisation as of September 2026, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.
- NHS England
- Not routinely funded
Sources: NICE search: fluoroestradiol F-18. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2020 | Detection of ER-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Fluoroestradiol F-18" OR ABSTRACT:"Fluoroestradiol F-18" OR TITLE:"FES PET" OR ABSTRACT:"FES PET" OR TITLE:"Cerianna" OR ABSTRACT:"Cerianna") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Fluoroestradiol F-18 (FES PET), not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductFluciclovine F-18
Shares PET (positron emission tomography), PET/CT and the tags gap-fill, diagnostic.
- ProductPegulicianine
Shares HR-positive / HER2-negative breast cancer and the tags gap-fill, diagnostic.
- ProductGallium-68 DOTATATE (and Cu-64 DOTATATE)
Shares PET/CT and the tags gap-fill, diagnostic.
- ProductTechnetium-99m tilmanocept
Shares HR-positive / HER2-negative breast cancer and the tags gap-fill, diagnostic.
- Product5-Aminolevulinic acid (oral, for glioma surgery)
Shares the tags gap-fill, diagnostic.
- ProductPafolacianine
Shares the tags gap-fill, diagnostic.
- ProductEribulin
Shares HR-positive / HER2-negative breast cancer and the tag gap-fill.
- TermCancer during pregnancy
Shares HR-positive / HER2-negative breast cancer and the tag gap-fill.